An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects with Huntington's Disease (HD) (STAIR)
Tolerability, Safety, and Activity of study drug SRX246 in Irritable Subjects With Huntington's Disease
Sponsor: National Institute of Neurological Disorders and Stroke
Enrolling: Male and Female Patients
Clinic Visits: 9
IRB Number: AAAQ7952
U.S. Govt. ID: NCT02507284
Contact: Ronda Clouse, RN: 212-305-2387 /
Additional Study Information: The purpose of this research study is to find out whether a new investigational drug called SRX246, which might be useful to Huntington's Disease (HD) patients who sometimes feel irritable, angry, or even aggressive, is well tolerated and safe when it is given two times a day by mouth at doses as high as 160 mg. As part of this study, we will use a number of questionnaires because we want to find out how much we can learn about how you feel based on the answers you give. This will let us and others plan future studies of medicines that may help HD patients control their temper better. This study will compare SRX246 to placebo. The placebo looks like the study drug, SRX246 capsules, but contains no active study drug. You will have a 2 out of 3 chance of being assigned to SRX246. You will have a 1 out of 3 chance of being assigned to placebo.
This study is closed
Karen Marder, MD, MPH
Do You Qualify?
Do you have any motor, cognitive, or behavioral symptoms of Huntington's Disease? Yes No
Would you or a family member consider yourself to be irritable? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Ronda Clouse, RN